Kazia Therapeutics Ltd ADR
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $126.5M
- Price
- $9.29
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.32%
- Volume
- 133.5K
About
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children’s Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
Quick stats
Shares outstanding13.6M
Computed float4.5M
Float / shares33.2%
Cash runway (months)66.3
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001075880
AI Summary
AI-generated1/16
minorbullishclinical trial
Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders
Sovargen has dosed the first patient in a Phase 1b/2a trial of paxalisib for intractable epilepsy linked to focal cortical dysplasia type 2 and tuberous sclerosis complex, triggering a $2 million development milestone payment to Kazia.
Under the March 2024 exclusive licensing deal, Sovargen develops and commercializes paxalisib for mTORopathy-related epilepsies worldwide excluding mainland China, Hong Kong, Macao and Taiwan; Kazia remains eligible for up to $17 million in further milestones plus sub-licensing revenue share and royalties on net sales.
For Kazia, the milestone adds non-dilutive cash and external validation of paxalisib's mechanism beyond oncology, while the company's own clinical focus for the asset stays on cancer, including post-GBM AGILE registrational planning.
Red flags
- Milestone cash ($2M now, up to $17M potential) is modest relative to typical clinical-stage burn and no cash runway update was provided
- Boilerplate risk language flags the company's ability to maintain NASDAQ listing compliance — worth checking KZIA's current listing status
- No new efficacy or safety data; timing of Phase 1b/2a readouts and enrollment targets not disclosed